11:47 AM EST - BioMS Medical Corp. : reported that Spectral Diagnostics has received Investigational Device Exemption or IDE approval from the U.S. Food and Drug Administration for Toraymyxin. Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxin, a therapeutic hemoperfusion device for the treatment of severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxin in the United States. BioMS Medical Corp.
shares T.MS are trading up $0.035 at $0.41.
